Faculty Profiles - Umakoshi Noriyuki

Papers - Umakoshi Noriyuki

Division display 21 - 40 of about 64 ／ All the affair displays >>

腎癌に対する経皮的凍結療法とロボット支援下腎部分切除術の対費用効果についての後方視的比較検討(Percutaneous Cryoablatin vs Robot-Assisted Partial Nephrectomy in Renal Carcinoma: Cost Analysis)

宇賀麻由, 別宮謙介, 山野井友昭, 永田翔馬, 宗友一晃, 馬越紀行, 川端隆寛, 冨田晃司, 松井裕輔, 生口俊浩, 郷原英夫, 荒木元朗, 平木隆夫

日本インターベンショナルラジオロジー学会雑誌 38 ( Suppl. ) 211 - 211 2023.4

高リスク隣接臓器が接触した腎悪性腫瘍に対する経皮的凍結療法(Percutaneous Cryoablation for Malignant Renal Tumors Contacting with High-risk Adjacent Organs)

Nagata Shoma, Matsui Yusuke, Tomita Koji, Uka Mayu, Umakoshi Noriyuki, Kawabata Takahiro, Munetomo Kazuaki, Iguchi Toshihiro, Hiraki Takao

日本医学放射線学会学術集会抄録集 82回 S160 - S160 2023.3

転移性腎腫瘍に対する経皮的凍結療法安全性と有効性の後方視的評価(Percutaneous Cryoablation for Metastatic Renal Tumors: A Retrospective Evaluation of Safety and Efficacy)

Kawabata Takahiro, Matsui Yusuke, Tomita Koji, Uka Mayu, Umakoshi Noriyuki, Munetomo Kazuaki, Nagata Shoma, Iguchi Toshihiro, Hiraki Takao

日本医学放射線学会学術集会抄録集 82回 S160 - S160 2023.3

下腿に発生した多発性グロムス腫瘍の1例

衣笠里菜, 馬越紀行, 浅野雄大, 児島克英, 檜垣文代, 槇本怜子, 大川七子, 松井裕輔, 平木隆夫

Japanese Journal of Radiology 41 ( Suppl. ) 48 - 48 2023.2

鼠径部高位穿刺による外腸骨動脈損傷に対し,バイアバーンを留置し救命しえた1例

櫻井淳暢, 宗友一晃, 冨田晃司, 永田翔馬, 川端隆寛, 馬越紀行, 宇賀麻由, 松井裕輔, 生口俊浩, 平木隆夫

日本インターベンショナルラジオロジー学会雑誌 37 ( 1 ) 58 - 58 2023.2

パワードライバー骨生検針の初期使用経験

高橋優花, 馬越紀行, 永田翔馬, 宗友一晃, 川端隆寛, 宇賀麻由, 冨田晃司, 松井裕輔, 生口俊浩, 平木隆夫

日本インターベンショナルラジオロジー学会雑誌 37 ( 1 ) 59 - 59 2023.2

経皮的ドレナージにて治療しえた大網膿瘍の1例

山田実典, 宇賀麻由, 宗友一晃, 馬越紀行, 冨田晃司, 松井裕輔, 生口俊浩, 平木隆夫, 垣内慶彦, 黒田新士

Japanese Journal of Radiology 41 ( Suppl. ) 41 - 41 2023.2

腎生検で診断された腎良性腫瘍の2例

白石明日香, 宗友一晃, 山田実典, 永田翔馬, 馬越紀行, 川端隆寛, 宇賀麻由, 冨田晃司, 松井裕輔, 生口俊浩, 平木隆夫

Japanese Journal of Radiology 41 ( Suppl. ) 41 - 41 2023.2

多発脾動脈瘤の1例

馬越紀行, 松井裕輔, 宗友一晃, 宇賀麻由, 冨田晃司, 生口俊浩, 平木隆夫

Japanese Journal of Radiology 41 ( Suppl. ) 41 - 41 2023.2

経皮的鼠径リンパ節穿刺によるリンパ管塞栓術が奏功した難治性リンパ漏の2例

衣笠里菜, 宇賀麻由, 宗友一晃, 馬越紀行, 川端隆寛, 冨田晃司, 松井裕輔, 生口俊浩, 平木隆夫

日本インターベンショナルラジオロジー学会雑誌 37 ( 1 ) 60 - 60 2023.2

腎癌定位放射線治療のフィデューシャルマーカーとして血管内コイルを留置した2例

永田翔馬, 冨田晃司, 宇賀麻由, 井原弘貴, 馬越紀行, 川端隆寛, 宗友一晃, 衣笠里菜, 山田実典, 松井裕輔, 吉尾浩太郎, 杉山聡一, 平木隆夫, 生口俊浩

Japanese Journal of Radiology 41 ( Suppl. ) 49 - 49 2023.2

診療科横断的アプローチにより救命し得た外傷性大動脈解離および肝損傷の1例

武川真也, 宇賀麻由, 永田翔馬, 宗友一晃, 馬越紀行, 川端隆寛, 冨田晃司, 松井裕輔, 生口俊浩, 平木隆夫, 内藤宏道, 上田浩平, 廣田真規

Japanese Journal of Radiology 41 ( Suppl. ) 47 - 47 2023.2

Magnetic Resonance Imaging Guidance for Percutaneous Needle Intervention Reviewed

Mayu Uka, Yusuke Matsui, Toshihiro Iguchi, Toshi Matsushita, Koji Tomita, Noriyuki Umakoshi, Takahiro Kawabata, Masanori Yamada, Takao Hiraki

Interventional Radiology 2023

Correction to: Correlation between renal ablation zone in contrast‑enhanced CT and non‑enhanced MRI during the early period following percutaneous cryoablation.

Noriyuki Umakoshi, Toshihiro Iguchi, Takao Hiraki, Yusuke Matsui, Koji Tomita, Mayu Uka, Soichiro Kajita, Motoo Araki, Toshiharu Mitsuhashi, Hideo Gobara, Susumu Kanazawa

Japanese journal of radiology 40 ( 12 ) 1316 - 1316 2022.12

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

Koji Tomita, Yusuke Matsui, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki

Japanese Journal of Radiology 40 ( 10 ) 1035 - 1045 2022.9

Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

Abstract

Purpose

This review aimed to summarize the treatment outcomes of percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) for metastatic liver tumors based on the findings of published studies over the last decade.

Materials and methods

Literature describing the survival outcomes of ablation therapy for liver metastases was explored using the PubMed database on April 26, 2022, and articles published in 2012 or later were selected. The included studies met the following criteria: (i) English literature, (ii) original clinical studies, and (iii) literature describing overall survival (OS) of thermal ablation for metastatic liver tumors. All case reports and cohort studies with fewer than 20 patients and those that evaluated ablation for palliative purposes were excluded.

Results

RFA was the most commonly used method for ablation, while MWA was used in several recent studies. RFA and MWA for liver metastases from various primary tumors have been reported; however, majority of the studies focused on colorectal cancer. The local control rate by RFA and MWA varied widely among the studies, ranging approximately 50–90%. Five-year survival rates of 20–60% have been reported following ablation for colorectal liver metastases by a number of studies, and several reports of 10-year survival rates were also noted.

Conclusion

Comparative studies of local therapies for colorectal liver metastases demonstrated that RFA provides comparable survival outcomes to surgical metastasectomy and stereotactic body radiation therapy.

DOI： 10.1007/s11604-022-01335-5

researchmap

Other Link： https://link.springer.com/article/10.1007/s11604-022-01335-5/fulltext.html

Percutaneous cryoablation combined with prior transcatheter arterial embolization for renal cell carcinomas of 3 cm or larger: a prospective study

Hideo Gobara, Yusuke Matsui, Mayu Uka, Koji Tomita, Noriyuki Umakoshi, Motoo Araki, Jun Sakurai, Toshihiro Iguchi, Takao Hiraki

International Journal of Clinical Oncology 27 ( 10 ) 1589 - 1595 2022.8

植込み型除細動器(ICD)リード交換後に生じた内胸動脈-腕頭静脈シャント塞栓術の1例

馬越紀行, 宇賀麻由, 宗友一晃, 小牧稔幸, 冨田晃司, 松井裕輔, 櫻井淳, 生口俊浩, 郷原英夫, 平木隆夫, 金澤右

日本インターベンショナルラジオロジー学会雑誌 36 ( 3 ) 320 - 320 2022.8

Clinical outcomes of image-guided percutaneous drainage of pericardial effusion in cancer patients: A single-center retrospective analysis. Reviewed International journal

Tetsuya Hasegawa, Yasuaki Arai, Miyuki Sone, Shunsuke Sugawara, Chihiro Itou, Shinji Wada, Noriyuki Umakoshi, Takatoshi Kubo, Shintaro Kimura, Masahiko Kusumoto

Asia-Pacific journal of clinical oncology 2022.7

Language：English Publishing type：Research paper (scientific journal)

AIM: Catheter removal, survival, and recurrence rates after percutaneous pericardial effusion drainage in cancer patients are not fully understood. We evaluated the clinical outcomes of image-guided percutaneous pericardial effusion drainage in cancer patients. METHODS: From January 2014 to September 2017, 113 percutaneous drainages for symptomatic pericardial effusion were performed in 100 cancer patients (median 60 years; range, 7-84 years) using ultrasound or angio-computed tomography. An 8-Fr drainage catheter was placed using the Seldinger technique via the subxiphoid (n = 73), apical (n = 23), or left parasternal (n = 17) routes. Success rates, complications, and postprocedural clinical outcomes of drainages were retrospectively assessed. RESULTS: The technical and clinical success rates were 100% and 99%, respectively, without major complications. The median duration of catheterization and evacuated pericardial effusion volume were 6 days (range, 1-72 days) and 970 ml (range, 140-7635 ml), respectively. Catheters were removed after the first drainage in 86 cases (86%). Symptomatic pericardial effusion recurred in nine patients after catheter removal, in whom redrainages were performed 13 times with a median duration to redrainage time of 48 days (range, 13-529 days). During the follow-up period (median 106 days [range, 1-1396 days]), 61 patients died. The median survival was 140 days (95% confidence interval [CI], 95-276 days), and the median catheter-free survival was 111 days (95% CI, 60-152 days). CONCLUSIONS: Image-guided percutaneous pericardial effusion drainage for cancer patients is safe and helps alleviate symptoms. Additionally, catheter removal is possible in most patients, allowing a catheter-free period for patients.

DOI： 10.1111/ajco.13810

PubMed

researchmap

Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review

Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki

Japanese Journal of Radiology 40 ( 10 ) 1024 - 1034 2022.7

Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

Abstract

The aim of this review was to summarize the latest evidence on image-guided thermal ablation therapies for lung metastases. PubMed was used to search for relevant articles that reported the oncological outcomes of thermal ablation for metastatic lung tumors, and those published in 2010 or later were selected for review. Ablative therapies were applied for lung metastases from various types of primary tumors, but most commonly colorectal ones. Radiofrequency ablation (RFA) was the most evaluated technique, followed by microwave ablation (MWA). The local control rates of ablative therapies were generally favorable, approximately 80–90% in many studies. Representative studies demonstrated promising overall survival rates of approximately 50% or higher 5 years after ablation for lung metastases from colorectal cancer or mixed types of primary tumors. Nevertheless, the survival outcomes varied depending on the type of primary tumor and background factors of patients such as other metastases and comorbidities. Several studies had aimed to compare the outcomes of various ablative therapies such as RFA, MWA, and cryoablation; however, conclusive data are not yet available to determine the most appropriate ablation modality for lung metastases. Further data accumulation is needed, especially for long-term outcomes and comparisons with other therapies.

DOI： 10.1007/s11604-022-01302-0

researchmap

Other Link： https://link.springer.com/article/10.1007/s11604-022-01302-0/fulltext.html

Percutaneous cryoablation for clinical T3a renal cell carcinoma (< 7 cm) with segmental vein involvement or perinephric fat invasion based on preoperative evaluation of high-resolution multidetector computed tomography scan

Mayu Uka, Toshihiro Iguchi, Nanako Okawa, Yusuke Matsui, Koji Tomita, Noriyuki Umakoshi, Kazuaki Munetomo, Hideo Gobara, Motoo Araki, Takao Hiraki

Japanese Journal of Radiology 40 ( 11 ) 1201 - 1209 2022.6

Publishing type：Research paper (scientific journal) Publisher：Springer Science and Business Media LLC

Abstract

Purpose

To retrospectively assess the feasibility, safety, renal function, technique efficacy rate, and survival of patients with clinical T3a renal cell carcinoma (RCC).

Materials and methods

Sixteen cryoablation sessions were performed in 14 patients (10 men; mean age, 69.8 ± 10.5 years; range, 49–90 years) with 14 clear cell T3a RCCs (mean, 3.3 ± 0.9 cm; range, 1.9–5.2 cm). One patient was on dialysis. Transcatheter arterial embolization was performed before cryoablation in 15 sessions. The primary endpoint was the technique efficacy rate. The secondary endpoints included feasibility, safety, renal function, and survival.

Results

Cryoablation was technically successful in all RCC cases. In two RCCs, cryoablation was performed twice because of local tumor progression. No major adverse events were observed. All patients were alive without metastases, with a median follow-up of 45 months (6−93 months). Complete response was achieved by cryoablation in 11 RCCs (78.6%). The primary and secondary technique efficacy rates were 77.1% and 84.4% at 1 year, 57.9% and 73.9% at 3 years, and 57.9% and 73.9% at 5 years, respectively. One patient underwent dialysis given a total contralateral nephrectomy due to another RCC 1 month after initial cryoablation and a total ipsilateral nephrectomy 46 months after initial cryoablation due to local progression. Except for two dialysis patients, of the 12 patients with a median follow-up of 41 months (6–93 months), none were on dialysis.

Conclusion

Cryoablation was safe and effective in T3a RCC, which mainly involved the renal venous branches and may represent an alternative treatment for inoperable patients.

DOI： 10.1007/s11604-022-01297-8

researchmap

Other Link： https://link.springer.com/article/10.1007/s11604-022-01297-8/fulltext.html

　 PREV - NEXT 　

< Umakoshi Noriyuki >

Papers - Umakoshi Noriyuki